Navigation

NEWS RELEASES

Search all of our news releases here.

Try these: Jeff GalvinC. David PauzaHIVFDAAmerican Gene Technologies

LGBT+ investment firm Gaingels joins American Gene Technologies’ mission to cure HIV, and other serious human diseases

LGBT+ Investment Firm Gaingels Joins American Gene Technologies’ Mission to Cure HIV, and Other Serious Human Diseases

Apr 14, 2021

ROCKVILLE, Md., Apr. 15, 2021 /PRNewswire/ – American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical… [Read More]

American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV

Nov 10, 2020

ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated… [Read More]

American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

Oct 8, 2020

ROCKVILLE, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s… [Read More]

FDA Approves American Gene Technologies (AGT) To Move Forward With Phase 1 Clinical Trial Of HIV Cure Program

Aug 11, 2020

ROCKVILLE, Md., Aug. 11, 2020 /PRNewswire/ — American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program. AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area,… [Read More]

Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure

Aug 3, 2020

ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), an internationally recognized advanced gene and cell therapy company in Rockville, MD, today announced a coauthored article by scientists from AGT and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National… [Read More]

American Gene Technologies (AGT) Moves HQ to New Facility, Expands Lab Space for HIV and Cancer Cure Research – Across From National Cancer Institute Campus

Jul 28, 2020

Click on images to view larger ROCKVILLE, Md., July 28, 2020 — American Gene Technologies (AGT), an internationally recognized leading gene and cell therapy company in Rockville, Maryland, today announced it has leased a spacious, modern facility in the Maryland life sciences corridor, across from… [Read More]

American Gene Technologies to Present at 2020 Inborn Errors of Metabolism Drug Development Summit in Boston

Mar 10, 2020

ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), a leading gene and cell therapy company in Rockville, Maryland, is pleased to announce its Chief Science Officer C. David Pauza, Ph.D will present at the Inborn Errors of Metabolism Drug Development Summit in Boston,… [Read More]

American Gene Technologies To Attend J.P. Morgan Healthcare Conference 2020

Jan 8, 2020

ROCKVILLE, MD, January 8, 2020 – American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the 38th annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 12-16 in San Francisco, California. American Gene Technologies’ second invitation… [Read More]

American Gene Technologies Hosts Celebration Event For Its First IND Submission (For HIV) To The Food and Drug Administration (FDA)

American Gene Technologies Hosts Celebration Event For Its First IND Submission (For HIV) To The Food and Drug Administration (FDA)

Nov 6, 2019

Press release also featured on:  GlobeNewswire.com ROCKVILLE, MD, November 06, 2019 – American Gene Technologies (AGT) announced today it will host a red carpet event tonight to celebrate a significant milestone in the company’s 11-year history of scientific research in cell and gene therapy: AGT successfully… [Read More]

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

Oct 18, 2019

ROCKVILLE, Md., Oct. 18, 2019 /PRNewswire/ — American Gene Technologies (AGT) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, which is potentially a single-dose, lentiviral vector-based gene therapy developed for the purpose of eliminating HIV from people infected with the… [Read More]

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media